Angelo Kanellos, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Angiodynamics, Inc. at 36.0% of the total. Reporting peaked in 2021 at $4,011 and has fallen 88.5% since, to $462 in 2025.
Across 143 payments — averaging $78.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$4K
- Exelixis Inc.$1K
- Johnson & Johnson$1K
- Cipla USA Inc.$1K
- EDAP Technomed Inc$541
- Astellas Pharma US Inc$481
- plus $2K from 26 others
What the payments were for
- Consulting fees$7587%
- Speaking & faculty fees$1,47013%
- Travel & lodging$3,47331%
- Food & beverage$4,90143%
- Education$6546%
- Entertainment$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 18 | $4,059 |
| Exelixis Inc. | 1 | $1,470 |
| Johnson & Johnson | 23 | $1,380 |
| Cipla USA Inc. | 1 | $1,095 |
| EDAP Technomed Inc | 4 | $541 |
| Astellas Pharma US Inc | 14 | $481 |
| AbbVie(2 entities) | 22 | $418 |
| Sumitomo Pharma America, Inc. | 3 | $282 |
| Merck | 7 | $204 |
| Myriad Genetic Laboratories, Inc. | 7 | $175 |
| Progenics Pharmaceuticals, Inc. | 2 | $145 |
| Intuitive Surgical | 1 | $123 |
| Myovant Sciences Inc. | 5 | $101 |
| Verity Pharmaceuticals Inc. | 2 | $84 |
| Boston Scientific | 4 | $77 |
| Procept Biorobotics Corporation | 2 | $73 |
| Bayer | 4 | $71 |
| Accord Healthcare, Inc. | 3 | $69 |
| Dendreon Pharmaceuticals LLC | 3 | $61 |
| Amgen | 3 | $51 |
| Janssen Scientific Affairs, LLC | 1 | $43 |
| AstraZeneca | 2 | $43 |
| Agiliti Surgical, Inc. | 1 | $37 |
| Koelis Inc. | 1 | $37 |
| 180 Medical, Inc. | 2 | $33 |
| Urogen Pharma, Inc. | 1 | $32 |
| Pfizer | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Blue Earth Diagnostics | 1 | $15 |
| Profound Medical Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$3,900
- Cabometyx$1,470
- ZEMDRI (PLAZOMICIN)$1,095
- Erleada$758
- ORGOVYX$259
- PYLARIFY$125
- Da Vinci Surgical System$123
How this compares
$11,289 in reported general payments places this provider in the 70th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 175 | $2,374,405 |
| ErleadaApalutamide | 106 | $1,449,464 |
| NubeqaDarolutamide | 74 | $1,007,227 |
| OrgovyxRelugolix | 309 | $804,286 |
| Abiraterone Acetate | 279 | $287,622 |
| XgevaDenosumab | 79 | $270,641 |
| MyrbetriqMirabegron | 13 | $13,077 |
| Tamsulosin Hcl | 372 | $6,551 |
| Tolterodine Tartrate ErTolterodine Tartrate | 36 | $2,883 |
| Prednisone | 261 | $1,809 |
| Finasteride | 104 | $1,440 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $1,145 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 41 | $1,003 |
| Testosterone | 13 | $634 |
| Testosterone Cypionate | 13 | $554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $481 | $2,387,482188 claims |
| Johnson & JohnsonErleada | $1,380 | $1,449,464106 claims |
| BayerNubeqa | $71 | $1,007,22774 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $282 | $804,286309 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $43 | $287,622279 claims |
| AmgenXgeva | $51 | $270,64179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 63 urology providers in Nevada.
Other urology in Reno
- Christopher EvansReno$184K
- Eric KimReno$24K
- Nicholas HauserReno$12K
- Timothy SuttleReno$8K
- Ross AndersonReno$7K
- Matthew McCormackReno$3K
- Chloe ShenkReno$3K
- Christopher TamReno$3K
- Dielle DuvalReno$3K
- Remy LambertsReno$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.